Holly Poplin, APRN
Primary Care · Little River, SCNPI 1134736309
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $952 and has fallen 97.9% since, to $20 in 2024.
Across 104 payments — averaging $14.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$303
- AbbVie$282
- Lilly USA, LLC$119
- GSK$111
- Astellas Pharma US Inc$94
- Amarin Pharma, Inc.$82
- plus $511 from 19 others
What the payments were for
- Food & beverage$1,503100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 22 | $303 |
| AbbVie | 21 | $282 |
| Lilly USA, LLC | 10 | $119 |
| GSK | 7 | $111 |
| Astellas Pharma US Inc | 6 | $94 |
| Amarin Pharma, Inc. | 5 | $82 |
| AstraZeneca | 5 | $68 |
| Amgen | 3 | $48 |
| Johnson & Johnson | 3 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $41 |
| Daiichi Sankyo Inc. | 2 | $37 |
| Novartis | 2 | $37 |
| Bayer | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| Upsher-smith Laboratories LLC | 1 | $21 |
| Biogen | 1 | $20 |
| Optinose US, Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Antares Pharma, Inc. | 1 | $14 |
| Pfizer | 1 | $13 |
| Boston Scientific | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Eisai Inc. | 1 | $12 |
| Esperion Therapeutics, Inc. | 1 | $12 |
How this compares
$1,503 in reported general payments places this provider in the 65th percentile of 115 primary care providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 181 | $5,557 |
| PaxlovidNirmatrelvir/Ritonavir | 52 | $4,288 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 275 | $2,261 |
| Doxycycline Hyclate | 267 | $2,240 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 148 | $1,654 |
| Triamcinolone Acetonide | 70 | $1,137 |
| Ofloxacin | 29 | $965 |
| Cephalexin | 107 | $808 |
| Ventolin HfaAlbuterol Sulfate | 12 | $676 |
| Ciprofloxacin Hcl | 101 | $602 |
| Azithromycin | 133 | $511 |
| Prednisone | 325 | $494 |
| Nystatin | 33 | $366 |
| Cefdinir | 16 | $355 |
| ValacyclovirValacyclovir Hcl | 23 | $334 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPaxlovid | $13 | $4,28852 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 115 primary care providers in South Carolina.
Other primary care in Little River
- Sarah TomashefskiGreenville$23K
- Samantha VaughtNorth Myrtle Beach$15K
- Cynthia SmithSeneca$10K
- William ByrdSumter$10K
- Kathleen BoonePawleys Island$9K
- Amanda GroomeGreenville$9K
- Holly SurrencyAiken$8K
- Jessica BoldenAnderson$8K
- Caren ArnetteDillon$7K
- Heather MartinSeneca$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.